Parker et al. have recently described a biomarker panel for ccRCC consisting of Ki-67, survivin, and B7-H1 (named Bioscore), which increased the CI of UISS from 0.774 to 0.819 and the CI of SSIGN algorithm from 0.821 to 0.837.[27] These demonstrate the contribution of molecular markers to enhance the power of clinical prognostic models in predicting long-term outcomes and risk of recurrent disease in localized ccRCC. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.